Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Rest of World
Net Revenue	$ 101,489	$ 83,612
U.S.
Rest of World
Net Revenue	92,258	74,343
Rest of World
Rest of World
Net Revenue	9,231	9,269
Drug Revenues
Rest of World
Net Revenue	46	2,338
Drug Revenues | U.S.
Rest of World
Net Revenue	0	0
Drug Revenues | Rest of World
Rest of World
Net Revenue	46	2,338
Concentrate Products
Rest of World
Net Revenue	101,443	81,274
Concentrate Products | U.S.
Rest of World
Net Revenue	92,258	74,343
Concentrate Products | Rest of World
Rest of World
Net Revenue	9,185	6,931
License Fee – Over time | Drug Revenues
Rest of World
Net Revenue	46	2,338
License Fee – Over time | Drug Revenues | U.S.
Rest of World
Net Revenue	0	0
License Fee – Over time | Drug Revenues | Rest of World
Rest of World
Net Revenue	46	2,338
License Fee – Over time | Concentrate Products
Rest of World
Net Revenue		1,472
License Fee – Over time | Concentrate Products | U.S.
Rest of World
Net Revenue		1,472
License Fee – Over time | Concentrate Products | Rest of World
Rest of World
Net Revenue		0
Product Sales – Point-in-time | Concentrate Products
Rest of World
Net Revenue	101,443	79,802
Product Sales – Point-in-time | Concentrate Products | U.S.
Rest of World
Net Revenue	92,258	72,871
Product Sales – Point-in-time | Concentrate Products | Rest of World
Rest of World
Net Revenue	$ 9,185	$ 6,931